Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma

Next Previous
Trial Profile

A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs ABY 029 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Diagnostic use

    • Most Recent Events

    • 05 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 05 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top